Stroke
October 2015 across all trials, the total number of events observed in these trials was small (<100) and risk factors for periprocedural MI remain unknown. We have recently shown that a simple rule (sex, contralateral occlusion, age, and restenosis [SCAR] rule) could help selecting patients with a similar risk of periprocedural stroke or death after CAS and CEA, 18 but risk factors for MI might also need to be considered. Therefore, we updated our systematic review to (1) assess the absolute risk of periprocedural MI and the absolute risk of periprocedural death after CAS and CEA and (2) identify whether risk factors for these outcomes differ between the 2 interventions.
Methods
We updated our previous systematic reviews or reports of procedural risks of CEA and CAS, 18, 19 for the period October 1, 2011, until June 30, 2014 , following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations for reporting. 20 
Selection Criteria
Eligible studies were those that enrolled patients with symptomatic or asymptomatic stenosis in the region of the carotid bifurcation, treated by CAS or CEA, and in which the numbers of MI or death could be extracted for any subgroup among 9 predefined risk factors: age (≥75-80 versus <75-80 years), contralateral carotid occlusion, coronary artery disease, diabetes mellitus, sex (men versus women), hypertension, peripheral artery disease, type of stenosis (restenosis after CEA versus primary atherosclerotic disease), and clinical presentation (symptomatic versus asymptomatic stenosis). Studies were considered irrespective of setting and language. We excluded studies that enrolled only specific populations (eg, postradiation stenosis, restenosis after CEA, and patients treated in an emergency context) and case reports.
For estimation of relative risks (RRs), we included all studies that reported periprocedural risk (that could be periprocedural, intrahospital, or within 30 days after intervention). For estimation of absolute risks, we included studies that reported the risks at 30 days only.
Search Strategy
The search strategy was based primarily on electronic searches of 3 databases (Medline, Embase, and Cochrane Library database) from 1980 to June 30, 2014 (Table I in the online-only Data Supplement). We hand-searched the references of all included studies and any relevant reviews. We also searched books of abstracts from recent conferences that are available online, the US Food and Drug Administration and the European Medicines Agency databases. We contacted 17 authors of studies published after 2003 with data on the risk of periprocedural MI but with data unavailable on subgroups. We also added a retrospective registry from the Department of Vascular Surgery of our hospital (Caen University Hospital, France) of all patients treated by CEA from 2000 to 2013. In case of multiple publications referred to the same population, we retained that with the largest sample or the most relevant for the studied subgroup.
Analysis

Absolute Risk
Proportions of MI and death were calculated after CAS and CEA. Each individual proportion was first transformed into a quantity with the Freeman-Tukey variance stabilizing transformation. 21 A weighted mean of the transformed proportions was computed by using a DerSimonianLaird random-effects model. 22 The combined proportion was calculated as the back-transform of this weighted mean. 23 We estimated the median year of the period of inclusion (midcohort year) and analyzed the evolution of the absolute risks over time by metaregressions.
Relative Risks
For each of the 9 potential risk factors and separately for studies of CAS and CEA, we calculated the RR of a periprocedural event in patients with versus those without the risk factor. Because of differences between studies in which the risk factor data were reported, the numbers of studies (and patients) included in each meta-analysis differed. When zero cell count was observed in 1 or both groups (ie, patients with and without the risk factor), we used a continuity correction, by adding a factor proportional to the reciprocal of the size of the contrasting study group to all cells. 24 Homogeneity of RR across studies in each metaanalysis was assessed using the I 2 statistic. I 2 >30% represents moderate heterogeneity, I 2 >50% substantial heterogeneity, and I 2 >70% considerable heterogeneity. For each risk factor, we assessed whether the effect on the risk of periprocedural event differed between CAS and CEA by performing an interaction test using random-effects metaregressions.
As recommended for such analyses, we considered a value of P≤0.10 as evidence for statistically significant interaction. 25 Statistical analyses were performed with SAS 9.2, STATA 11.0 and R.
Results
Of the 1584 articles identified from our update of the electronic searches, 147 abstracts were screened, 140 references were retrieved for assessment in full text, and 96 references were finally eligible ( Figure II in the online-only Data Supplement).
In addition, we added 202 references obtained from other sources: (1) 200 references from our previous systematic review 18 ; (2) 1 reference from our own registry from the Department of Vascular Surgery (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) ; (3) 1 reference for which unpublished data were obtained (ie, the only author who replied). 26 First, these 202 references and the 96 references obtained from electronic searches were screened, and second, we excluded 25 references corresponding to duplicated publications referring to same population. Therefore, 273 references were included corresponding to 120 independent populations. The list of all references included in the systematic review is available in the online-only Data Supplement.
Thirty-Day Absolute Risk of MI
We included 52 independent studies of CEA (62 336 patients) and 68 of CAS (31 843 patients) for the calculation of the 30-day absolute risk of MI. The characteristics of these studies and those of the 1609 patients from our own registry and the list of all references included in the systematic review are shown in Tables II and III in the online-only Data Supplement.
Only 29 (56%) of the 52 CEA studies and 13 (19%) of the 68 CAS studies provided an explicit definition of MI. The Table shows that MI definitions varied across studies, being based on clinical parameters (chest pain suggestive of coronary ischemia), biology (elevation of myocardial necrosis enzymes levels such as creatine kinase, creatine kinase-MB, or troponin), and ECG changes (development of pathological Q waves, new significant ST-segment changes or T-wave changes, or new left bundle branch block). Definitions did not differ between CEA and CAS studies although they tended to be more specific in CAS studies. In our registry, MI is defined as a chest pain associated with ECG changes (development of pathological Q waves, new significant ST-segment changes or T-wave changes, or new left bundle branch block) and elevation of troponin higher than the laboratory limit.
The pooled absolute risk of MI was 0.87% (95% CI, 0.69-1.07; I I 2 =59%) after CAS (P int =0.38). In metaregression analyses using the midcohort year as covariate, the absolute risk of MI did not vary over time in either CEA studies (since 1980; P=0.54) or CAS studies (since 1990; P=0.87; Figure III in the online-only Data Supplement).
Thirty-Day Absolute Risk of Death
We included 99 independent studies of CEA (274 765 patients) and 83 of CAS (39 184 patients) for the calculation of the 30-day absolute risk of death. The pooled absolute risk of death was 0.92% (95% CI, 0.79-1.08; I 2 =88%) after CEA and 1.03% (95% CI, 0.83-1.26; I 2 =70%) after CAS (P int =0.62). In metaregression analyses, the risk of death slightly decreased over time in CEA studies (P<0.001) but did not change in CAS studies (P int =0.81). There was no interaction in these time-trends between CAS and CEA (P int =0.17; figure not shown).
Thirty-Day Proportion of Death Related to Stroke and MI
Thirty-five independent CEA studies (24 690 Figure 1 shows the RR of periprocedural MI according to the 9 potential risk factors. Symptomatic stenosis and restenosis were associated with a higher risk of MI, whereas male sex was associated with a lower risk of MI after CAS. Older age, coronary artery disease, peripheral . Meta-analyses of the relative risk (RR) of myocardial infarction (MI) after carotid angioplasty and stenting (CAS) and carotid endarterectomy (CEA) according to the 9 potential risk factors. n0 indicates number of events in patients without clinical factor; p0, number of patients without clinical factor; n1, number of events in patients with clinical factor; p1, number of patients with clinical factor; P het , Cochrane homogeneity test probability value; P int , P interaction; P sig , P significance; and s, number of studies. artery disease, and restenosis increased the risk of MI after CEA. Only the effect of sex differed between CAS and CEA with men being at lower risk of MI than with women after CAS, whereas there was no difference after CEA (P int =0.01). Figure 2 shows the RR of periprocedural death according to the 9 potential risk factors. There were no statistically significant differences between risk factors in studies of CAS versus studies of CEA, and all trends were in the same directions. However, statistical power was much greater in studies of CEA, and so only older age and symptomatic stenosis were significantly associated with a higher risk of death after CAS; older age, contralateral occlusion, coronary heart disease, diabetes mellitus, peripheral artery disease, and symptomatic stenosis were associated with a higher risk of death after CEA.
Risk Factors for Periprocedural MI
Risk Factors for Periprocedural Death
Discussion
We found that the 30-day absolute risk of MI was not significantly higher after CEA than after CAS (0.87% versus 0.70%), and that there were no major risk factors that could help to identify patients with a differential risk of MI after CEA versus CAS.
The absolute risk of MI we found after CEA was lower than the one found in the pooled analysis restricted to RCTs only (1.87%). By contrast, the absolute risk of MI after CAS was comparable with that observed in RCTs (0.75%). The risk of MI after CEA could have been underestimated because we included retrospective registries, but a similar underestimation should have been found for CAS. As overall, CEA registries were performed earlier than CAS registries, and because definition of MI has changed over time, there is a possibility that MI was less likely to be diagnosed in the past. However, we did not find any change in risks over time. Although RCTs have shown a 2× higher risk of MI after CEA than after CAS, the absolute difference is small and the reasons remain unclear. First, the use of combined antiplatelet therapy (aspirin/clopidogrel for at least 1 month) in CAS but not in CEA might explain the absolute difference between CAS and CEA. Combined antiplatelet therapy is less commonly used in patients scheduled for CEA because it seems to increase the risk of bleeding and to slow down healing. Second, the type of anesthesia differs between CEA and CAS. CAS is performed under local anesthesia, whereas , depending on centers, CEA is performed under general or locoregional anesthesia. The risk of stroke and death at 30 days does not differ between the 2 types of anesthetic techniques after CEA 27 ; however, there are few data on the risk of MI. In a large multicenter RCT, proportion of MI at 30 days after CEA was higher under local than under general anesthesia (0.5% versus 0.2%), but the difference did not significantly differ. 28 Thus, considering the few number of studies, it remains difficult to know the exact influence of anesthesia technique on the risk of MI after CEA and CAS. Third, cervical incision induces local inflammation, stress, and liberation of proinflammatory cytokines, which Figure 2 . Meta-analyses of the relative risk (RR) of death after carotid angioplasty and stenting (CAS) and carotid endarterectomy (CEA) according to the 9 potential risk factors. n0 indicates number of events in patients without clinical factor; p0, number of patients without clinical factor; n1, number of events in patients with clinical factor; p1, number of patients with clinical factor; P het , Cochrane homogeneity test probability value; P int , P interaction; P sig , P significance; and s, number of studies.
by guest on April 10, 2017 http://stroke.ahajournals.org/ Downloaded from causes prothrombotic state. This prothrombotic state could favor the risk of periprocedural MI after CEA. 29 Noncardiac vascular surgery (carotid artery, lower extremity artery, and abdominal aortic aneurysm) is associated with a risk of periprocedural MI, mainly because atherosclerosis is a systematic disease. In a meta-analysis, this risk has been estimated to vary between 1% and 26%. 16 As expected, in our study, the main risk factor for periprocedural MI was a history of coronary artery disease. The risk of periprocedural MI has never been compared in lower extremity artery between surgery and angioplasty/stenting; only few studies [30] [31] [32] reported this risk after surgery and only 1 33 after angioplasty/stenting. Thus, uncertainty remains on whether our results are specific or not of the carotid artery.
Sex had a differential association with the risk of MI between CAS and CEA. When compared with what we found for stroke and death, sex was the only factor that differed between the 2 techniques. 18 Men were at lower risk of MI than women after CAS. On the contrary, in our previous meta-analysis, male sex was associated with a lower risk of periprocedural stroke or death after CEA, whereas sex had no significant influence on the risk after CAS. Considering the huge number of studies included for this subgroup and the absence of heterogeneity in our analyses on MI, the association is likely to be genuine. However, it remains difficult to explain. No data are available on the influence of sex on the risk of periprocedural MI after angioplasty/stenting and surgery in other atherosclerotic arteries.
Our analysis has several potential limitations. First, the numbers of events were sometimes small and because of the population case-mix, our results on absolute risks were heterogeneous. However, this heterogeneity is common in meta-analyses of absolute risks. We consequently used random-effects models. In contrast, there was no or little heterogeneity in analyses of risk factors. Second, MI definitions have varied over time and between studies, especially the use of cardiac biomarkers has changed (creatine kinase appeared first then creatine kinase-MB, and troponin have now been used for over a decade). However, this has probably not substantially affected the estimate of the risk of MI. Diagnosis of MI in studies was based, when available, on the presence of several parameters (clinical symptoms and at least 1 biomarker or ECG changes). Because it is common knowledge that elevation of cardiac biomarkers can occur after carotid procedure, biomarkers elevation without symptoms suggestive of coronary ischemia or ECG changes were not included in the calculation of the absolute risk of MI. Furthermore, in spite of changes in MI definition over time, the absolute risk of MI has not changed over time. Third, we were unable to validate our results on sex in RCTs. Few RCTs have reported data on MI by sex. Moreover, the total number of events in these trials was too small to assess the validity of our results. Fourth, we only included studies that reported events in at least 1 of the 9 predefined subgroups for the calculation of the absolute risk of MI and death. However, this should not have introduced selection bias. On the one hand, we excluded some RCTs; on the other hand, the ones retained were the RCTs with larger sample size than those excluded and had, therefore, more precise estimations of absolute risks. In addition, only 8% of total of references eligible (from our previous systematic review and update) were excluded because of the absence of data on subgroup. Finally, apart dual antiplatelet therapy almost always used in CAS, we were unable to assess whether periprocedural medication differed between CEA and CAS because this information was scarcely reported.RCTs have shown that stroke is the main cause of periprocedural death after carotid revascularization.
2, [34] [35] [36] Our results confirm this finding. Risk factors for periprocedural stroke and death will, therefore, have most potential clinical utility in selecting the most appropriate intervention for individual patients. Although we found that male sex is associated with a lower risk of periprocedural MI than female sex after CAS, this should not be considered as a major criteria to select candidates for CAS, because MI is far less common than stroke, MI accounts for relatively few periprocedural deaths, and male sex is a strong risk factor for periprocedural stroke or death after CAS. The size of each circle is inversely proportional to the variance of the absolute risk. The absolute risk of MI according to mid-cohort year did not vary over time either in CEA studies (since 1980, p=0.54) or in CAS studies (since 1990, p=0.87 ).
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